'Agony of Choice' for Clinicians Treating Leukemia

With an abundance of targeted therapies transforming the treatment landscape for chronic lymphocytic leukemia, picking the optimal drug or regimen for the right situation can be a challenge.

Related Keywords

Austria ,Jan Paul Bohn ,Astrazeneca ,Ohio State University Comprehensive Cancer Center ,University Of Innsbruck Austria ,Medical University ,European Medical ,Refractory Disease ,Fixed Duration ,Chronic Lymphocytic Leukemia ,Hematology ,Leukemia ,Oncological Medicine ,Chemotherapy ,Biologic Therapy ,Precision Medicine ,Targeted Therapy ,Hemorrhage ,Bleeding ,B Cell Lymphoma ,Non Hodgkins Lymphoma ,Tolerance ,Toxicology ,Europe ,European ,Hypertension ,Immunomodulator ,Lenalidomide ,Tumor Lysis Syndrome ,Refractory ,